| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Original Article |
Chemical Pathology Department, West Middlesex University Hospital/Quest Diagnostics, Inc., Isleworth, Middlesex, United Kingdom TW7 6AF; Clinical Pharmacology, GlaxoSmithKline Research and Development, Greenford, Middlesex, United Kingdom UB6 0HE; Respiratory Therapeutic Group, GlaxoSmithKline, Uxbridge, United Kingdom UB11 1BT; and Department of Chemical Pathology, University College London Hospitals, London, United Kingdom W1T 4JF
Address all correspondence and requests for reprints to: Dr. R. Fink, West Middlesex University Hospital/Quest Diagnostics, Inc., Chemical Pathology Department, Isleworth, Middlesex, United Kingdom TW7 6AF. E-mail: richard.s.fink{at}questdiagnostics.com.
Abstract
Free cortisol in the urine (UFC) is frequently measured in clinical research to assess whether inhaled corticosteroids (ICS) cause suppression of the hypothalamic-pituitary-adrenal axis. Thirteen healthy male subjects received single inhaled doses (of molar equivalence) of fluticasone propionate (FP), triamcinolone acetonide (TAA), budesonide (BUD), and placebo in this single blind, randomized, cross-over study. UFC output was measured using four commercial immunoassays in samples collected in 12-h aliquots over 24 h. The cortisol production rate was assessed from the outputs of cortisol metabolites. UFC showed a 100% increase over placebo levels in the Abbott TDX assay after the administration of BUD. The other assays detected variable suppression (ranging from 2961% suppression for FP, 3062% suppression for TAA, and 25% suppression to 100% stimulation for BUD). Suppression was more pronounced in the first 12 h after TAA and in the second 12 h after FP. Similar suppression was found in each 12-h period after BUD. UFC estimation based on immunoassays after ICS may be an unreliable surrogate marker of adrenal suppression. Many of the published studies describing or comparing the safety of different ICS should be reevaluated, and some should be interpreted with caution.
This article has been cited by other articles:
![]() |
M. Masoli, M. Weatherall, S. Holt, P. Shirtcliffe, and R. Beasley Inhaled fluticasone propionate and adrenal effects in adult asthma: systematic review and meta-analysis Eur. Respir. J., November 1, 2006; 28(5): 960 - 967. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. K. Jerjes, N. F. Taylor, T. J. Peters, S. Wessely, and A. J. Cleare Urinary Cortisol and Cortisol Metabolite Excretion in Chronic Fatigue Syndrome Psychosom Med, July 1, 2006; 68(4): 578 - 582. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. P. Chrousos, L. Ghaly, A. Shedden, D. G. Iezzoni, and A. G. Harris Effects of Mometasone Furoate Dry Powder Inhaler and Beclomethasone Dipropionate Hydrofluoroalkane and Chlorofluorocarbon on the Hypothalamic-Pituitary-Adrenal Axis in Asthmatic Subjects Chest, July 1, 2005; 128(1): 70 - 77. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Pescollderungg, D. G. Peroni, A. Pietrobelli, and G. Radetti Inhaled Corticosteroids and Urinary Free Cortisol Pediatrics, December 1, 2003; 112(6): 1464 - 1465. [Full Text] [PDF] |
||||
![]() |
L Pescollderungg, G Radetti, E Gottardi, D G Peroni, A Pietrobelli, and A L Boner Systemic activity of inhaled corticosteroid treatment in asthmatic children: corticotrophin releasing hormone test Thorax, March 1, 2003; 58(3): 227 - 230. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |